For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback